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Autosomal recessive hypophosphatemic rickets (ARHR) is a heritable disorder
characterized by hypophosphatemia, osteomalacia, and poor bone development. ARHR
results from inactivating mutations in the DMP1 gene with the human phenotype being
recapitulated in the Dmp1 null mouse model which displays elevated plasma fibroblast
growth factor 23. While the bone phenotype has been well-characterized, it is not
known what effects ARHR may also have on skeletal, cardiac, or vascular smooth
muscle function, which is critical to understand in order to treat patients suffering from
this condition. In this study, the extensor digitorum longus (EDL-fast-twitch muscle),
soleus (SOL–slow-twitch muscle), heart, and aorta were removed from Dmp1 null mice
and ex-vivo functional tests were simultaneously performed in collaboration by three
different laboratories.Dmp1 null EDL and SOLmuscles produced less force than wildtype
muscles after normalization for physiological cross sectional area of the muscles. Both
EDL and SOL muscles from Dmp1 null mice also produced less force after the addition
of caffeine (which releases calcium from the sarcoplasmic reticulum) which may indicate
problems in excitation contraction coupling in these mice. While the body weights of
the Dmp1 null were smaller than wildtype, the heart weight to body weight ratio was
higher. However, there were no differences in pathological hypertrophic gene expression
compared to wildtype and maximal force of contraction was not different indicating that
there may not be cardiac pathology under the tested conditions. We did observe a
decrease in the rate of force development generated by cardiac muscle in the Dmp1
null which may be related to some of the deficits observed in skeletal muscle. There
were no differences observed in aortic contractions induced by PGF2α or 5-HT or in
endothelium-mediated acetylcholine-induced relaxations or endothelium-independent
sodium nitroprusside-induced relaxations. In summary, these results indicate that there
are deficiencies in both fast twitch and slow twitch muscle fiber type contractions in
this model of ARHR, while there was less of a phenotype observed in cardiac muscle,
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and no differences observed in aortic function. These results may help explain skeletal
muscle weakness reported by some patients with osteomalacia and need to be further
investigated.
Keywords: osteomalacia, DMP1, Autosomal recessive hypophosphatemic rickets, bone-muscle crosstalk,
sarcopenia, cardiovascular disease, skeletal muscle, cardiac muscle
INTRODUCTION
Hypophosphatemic rickets is caused by a group of genetic
disorders characterized by reduced renal phosphate transport,
bone malformation, and elevated fibroblast growth factor
23 (FGF23). FGF23 is primarily released by osteocytes
and osteoblasts and regulates serum phosphate levels by
increasing phosphate excretion in the kidney via regulation
of sodium-phosphate transporters as well as by reducing 1,25
(OH)2D levels (Shimada et al., 2004; Berndt and Kumar,
2007). The most common of these genetic disorders is X-
linked hypophosphatemia (XLH), followed by Autosomal
Recessive Hypophosphatemic Rickets (ARHR), Autosomal
Dominant Hypophosphatemic Rickets (ADHR), tumor-induced
osteomalacia (TIO), and others. ARHR1 (OMIM #241520)
is caused by mutations in Dentin Matrix Protein 1, DMP1
(Feng et al., 2006) whereas ARHR2 is caused by mutations in
ectonucleotide phyrophospatase/phosphodiesterase 1, ENPP1
(Lorenz-Depiereux et al., 2010). ARHR due to the DMP1
mutation is characterized by hypophosphatemia, osteomalacia,
and poor bone and tooth development and structure and we
have previously shown that FGF23 is elevated in osteocytes (Feng
et al., 2006; Farrow et al., 2009) similar to what occurs in XLH
(Liu et al., 2007; White et al., 2014).
DMP1 is considered to be an extracellular matrix protein
that belongs to the SIBLING (small integrin-binding ligand, N-
linked glycoprotein) family and regulates biomineralization. The
mechanisms responsible for DMP1-mediated bone changes still
remain to be completely elucidated. However, DMP1 is thought
to participate in mineralization via its role in extracellular
matrix formation, increase in Wnt/β-catenin, decrease in
expression of DKK1, an inhibitor of the Wnt/β-catenin signaling
pathway, and inhibition of FGF23 expression (Lu et al., 2011;
Feng et al., 2013; White et al., 2014). In regards to FGF23
expression, it is hypothesized that DMP1, together with PHEX
(phosphate-regulating gene with homologies to endopeptidases
on the X chromosome which is mutated in XLH), regulates
the expression/release of FGF23 by osteocytes as well as the
degradation of FGF23 (Martin et al., 2011, 2012; Lee et al.,
2014). It has also been hypothesized that DMP1 may directly
function as a transcription factor, however, recent data have
shown that targeted nuclear expression of DMP1 in osteocytes
and osteoblasts did not rescue the dental phenotype of DMP1 null
Abbreviations: CKD, chronic kidney disease; DMP, dentin matrix acidic
phosphoprotein; ARHR, autosomal recessive hypophosphatemic rickets; XLH, X-
linked hypophosphatemia; EDL, extensor digitorum longus muscle; SOL, soleus
muscle; FGF23, fibroblast growth factor 23; PCSA, physiological cross-sectional
area; ECC, excitation contraction coupling.
mice (Lin et al., 2014). Therefore the mechanism responsible for
DMP1 regulation of FGF23 is still not completely known.
While the bone phenotype of ARHR has been investigated,
very little is known about other organ systems that may also be
altered in ARHR or other genetic diseases of hypophosphatemic
rickets. In addition to bone abnormalities, families with ARHR
have also been reported to have nerve deafness, learning
disabilities, and dental abnormalities (Farrow et al., 2009; Makitie
et al., 2010). Our research group has been very interested in
the relationship between bone and muscle health and so we
specifically were interested in the skeletal, cardiac, and vascular
smooth muscle function of this condition. It has previously been
shown that XLH patients display muscle weakness and the Hyp
mouse model of XLH displays reduced strength (Aono et al.,
2011; Veilleux et al., 2013). Therefore, we wanted to determine
if the Dmp1 null mouse which closely mimics the human ARHR
phenotype with abnormal dentinogenesis, chondrogeneisis, and
mineralization (Ye et al., 2004, 2005; Ling et al., 2005; Feng et al.,
2006) also has muscle weakness. These findings would potentially
yield insights into common mechanisms for skeletal muscle
phenotypes between XLH and ARHR. For our study, Dmp1
null and wild-type (WT) mice were sacrificed and a fast-twitch,
glycolytic muscle (extensor digitorum longus muscle–EDL), a
slow-twitch oxidative muscle (soleus muscle–SOL), the heart and
aorta were removed and the contractile responses to various
challenges were studied. Importantly, a muscle phenotype was
identified which may have implications for ARHR patient health.
MATERIALS AND METHODS
Animals
Twenty-two to 30 week-old wild type (WT) and Dmp1 null mice
of both sexes were used in experiments. The Dmp1 null mice
were generated with exon 6 deletion as previously described
(Feng et al., 2003) and crossed on a C57BL/6 and 129 Sv mixed
background. All mice were housed in a temperature-controlled
(22± 2◦C) room with a 12-h:12-h light/dark cycle. Animals were
fed ad libitum. This study was carried out in accordance with the
recommendations and approval of the Institutional Animal Care
and Use Committee of the University of Missouri-Kansas City.
Genotyping
Mice were genotyped using DNA isolated from tail segments
obtained at weaning. Tail segments were digested in 10mM Tris-
HCl pH 8.0 containing 25mM EDTA, 0.5% SDS, 50mM NaCl,
and 0.5mg/ml proteinase K. A saturated solution of sodium
chloride was then added to the digests to precipitate residual
contaminating protein. Extracts were centrifuged for 25min at
room temperature and the DNA containing supernatant was
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precipitated using 80% isopropanol. Resulting pellets were then
washed with 70% ethanol and allowed to air dry. Dried pellets
were hydrated with 0.01M Tris-HCl buffer (pH 8.0) containing
1mM EDTA, and, the DNA concentration was determined by
UV spectrophotometry.
DNA samples were genotyped using PCR with gene
specific primers for Dmp1 [forward 5′-GAGTGCGAT
CTTCCTGAGGCCGATACTGTC-3′ and reverse 5′CGCGG
CTGAAATCATCATTAAAGCGAGTGG-3′] and WT [forward
5′-GCCCCTGGACACTGACCATAGC-3′ and reverse 5′-CTG
TTCCTCACTCTCACTGTCC-3′]. PCR products were evaluated
by electrophoresis on 2.1% agarose gels followed by staining with
ethidium bromide, and digitally imaged with a Fuji LAS4000
CCD scanner.
Tissue Extraction
Prior to use, mice were weighed and treated with heparin
(5000 units/kg bodyweight) by intraperitoneal injection 15min
prior to sacrifice by cervical dislocation. Mouse hearts were
quickly excised and placed into oxygenated Ringer’s solution
where residual blood was washed out and the atria were removed.
The thoracic aorta was excised, placed in Hank’s Buffered Salt
Solution (HBSS, Invitrogen, Carlsbad, CA), and blood, fat, and
excess connective tissues were carefully removed. As soon as the
heart and aorta were extracted, intact EDL, and SOL muscles
from the samemice were removed and placed in a dissecting dish
containing oxygenated Ringer’s solution where residual adipose
and connective tissue were then removed.
Skeletal Muscle Functional Studies
Isometric force data was collected for EDL and SOL muscles
(4 male /3 female mice) using an eight chambered system as
we have previously described (Thornton et al., 2011; Park et al.,
2012). Muscles bath experiments were run at room temperature,
gassed with 100% oxygen, and bathed in Ringer’s solution
(142mM NaCl2, 5mM KCl, 1.8mM MgCl2, 10mM HEPES,
2.5mM CaCl2, 10mM glucose, pH 7.4). Data were collected and
analyzed with PowerLab Software (AD Instruments; Colorado
Springs, CO) customized for these experiments. Muscles were
first equilibrated for 20min to mimic conditions of normal
activity (low duty cycle, ∼1%). They were then subjected to
the length-force relationship test to determine optimal length at
which maximal force is achieved. Muscles were stimulated with
a train of stimulation of 500ms of frequencies ranging from 1
to 130Hz at 1 ms pulses to generate force vs. frequency (FF)
relationships. From the FF, the frequency producing maximal
tetanic force (Tmax) was then used for the rest of the experiments.
Muscles were stimulated every minute with (Tmax) for 5–10min
to assure that the preparation was stable. At the end of this period,
muscles were treated with 5mM caffeine that effectively releases
calcium from the sarcoplasmic reticulum (SR) to test whether
excitation-contraction coupling (ECC) was defective at the end of
the recovery process. After ex-vivo contractility protocols, muscle
dimensions, and masses were measured for determination of the
normalized force corrected for physiological cross-sectional area
(PCSA) based on the following equation: Force (N/cm2)= [force
(g) × 0.00981 (m/s2) × muscle length (cm) × muscle density
(1.06 g/cm3)]/[muscle weight (g)].
Cardiac Contractility Measurements
Small heart clips were attached to the proximal septum and distal
apex (Harvard apparatus; Holliston, MA) and then attached to
a force transducer using silk thread running from the clips to
the transducer as we have previously described (Touchberry
et al., 2010). The intact hearts (7 male/3 female mice) were
hung vertically between bipolar platinum stimulating electrodes
suspended in 25-mL glass tissue chambers (AD Instruments,
Colorado Springs, CO) superfused with Ringer’s solution (NaCl
140mM, CaCl2 2.5mM, KCl 2.0mM, K2HPO4 1.5mM, MgSO4
1mM, HEPES 10mM, pH 7.4) continuously bubbled with
100% O2 at room temperature. Muscles were rinsed three
times and allowed to stabilize for 30min in these conditions
prior to experimentation. Maximum force of contraction was
determined at 10 V, 5ms duration, and 1 Hz frequency (Grass
stimulator SD 9; Quincy, MA) and hearts were stretched to the
length of maximal force development. The contractile data were
recorded and analyzed on Lab Chart 6 software; AD Instruments
(Colorado Springs, CO). The isometric tension during maximal
contraction of Dmp1 null and WT was normalized to heart
weight and is presented as mN/g. Waveform analysis was also
conducted for slope (mN/s), and the rate of relaxation, or tau,
during the period of maximal contraction for both Dmp1 null
and WT.
Cardiac Gene Expression Measurements
Total RNA was isolated from Dmp1 null and WT mouse
ventricles using the Total RNA isolation kits from IBI
Scientific (Peosta, IA). One step real-time RT-PCR was
performed as previously described (Wacker and Godard,
2005) using the TaqMan RNA-to-CT 1 step kit from Applied
Biosystems (Carlsbad, CA). Premade TaqMan primer/probes
for genes of interest as well as the housekeeping gene, β-actin,
were ordered from Applied Biosystems. Genes involved in
cardiac hypertrophy or heart failure which included atrial
naturietic peptide (ANP, Mm01255747_g1), skeletal muscle
α actin (SkAct, Mm00808218_g1), β-myosin heavy chain
(βMHC, Mm00600555_m1), α-myosin heavy chain (αMHC,
Mm00440359_m1), sarcoplasmic endoplasmic reticulum
calcium ATPase (SERCA2a2, Mm01201431_m1) as well as genes
involved in cardiac remodeling, vimentin (Mm01333430_m1),
and collagen 1a1 (Mm00801666_g1), were tested. Relative gene
expression was quantified by 2−1CT calculations utilizing β-actin
as the housekeeping gene. Fold change was then calculated by
dividing Dmp1 null by WT expression and the results were
averaged. One fold change equal expression to the WT and
is indicated by a dashed line in Figure 4. β-actin was chosen
as a housekeeping gene as Dmp1 null and WT had minimal
differences in β-actin gene expression.
Aortic Isometric Tension Myography
Aortic segments 3–4mm in length (8 male/5 female mice)
were mounted on pins in chambers of a DMT 610M wire
myograph system (Danish Myo Technology A/S, Aarhus N,
Denmark) containing Krebs buffer (in mM: 119NaCl, 4.7 KCl,
0.24NaHCO3, 1.18KH2PO4, 1.19 MgSO4, 5.5 glucose, and 1.6
CaCl2) saturated at 37
◦C with a gas mixture containing 20%
O2/5% CO2/75%N2 (Airgas Mid-South Inc., Tulsa, OK) at 37
◦C.
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Aortic rings were progressively stretched to 0.75 g equivalent
force passive tension in 0.1 g steps and allowed to equilibrate
for 45min as described previously (Silswal et al., 2011, 2012).
Force changes were recorded using an ADinstruments PowerLab
4/30 and associated LabChart Pro software (v6.1) running
on a standard Windows XP computer platform. To assess
the quality of the preparation before performing experiments,
aortic rings were exposed to isotonic KCl (40 and 80mM)
and a concentration response curve to prostaglandin F2α
(PGF2α; 1 nM-10 µM) or 5-HT (1 nM-10 µM) was performed.
The contraction response was followed by a concentration
response curve to acetylcholine (ACh; 1 nM-10 µM) to evaluate
endothelial-mediated relaxation. Similarly a relaxation response
curve was measured after the nitric oxide donor, sodium
nitroprusside (1 nM-10µM) was carried out after precontraction
with PGF2α to assess smooth muscle relaxation. Contraction
data was presented as g of tension and relaxation was presented
as a percent relaxation compared to the maximal contraction
produced by PGF2α or 5-HT.
Statistical Analysis
All graphs were made and statistical procedures were performed
using GraphPad Prism 6.0 or Origin 6.1. Data are presented as
means ± S.E.M. Skeletal and cardiac muscle contractility data
were compared using a paired t-test. Skeletal muscle sample
numbers included muscles from the right and left limbs of
the same animal. These muscles were averaged to yield one
independent sample. Cardiac muscle gene expression analysis
was compared using a one-way analysis of variance followed by
a Tukey Post-hoc adjustment. Aortic contraction and relaxation
experiments were analyzed using a two-way analysis of variance.
Significance levels were set at p< 0.05 for experiments.
RESULTS
Skeletal Muscle
In general, we analyzed data for gender differences, but found no
difference between male or female animals in skeletal, cardiac,
or vascular smooth muscle responses, therefore genders were
combined for final analysis in the three muscle types. For skeletal
muscle, we found that the Dmp1 null animals and skeletal
muscles were smaller than WT (Figures 1A,B, 2A; P < 0.05).
While there was no difference in the normalized weight of
the EDL, the SOL was smaller than WT after correcting for
BW (Figure 1C, P > 0.05; Figure 2B, P < 0.05). The absolute
force of both EDL and SOL of Dmp1 null mice was reduced
as compared to WT mice (Figures 1B, 2B; P < 0.05). After
normalizing the forces of all muscles to the PCSA (which
takes into account not only the mass, but also the length
and the density of the muscles), the normalized force was
reduced in both EDL and SOL (Figures 1D, 2C, P < 0.05).
These data indicate, that size alone did not account for the
reduced force of contraction. Skeletal muscles depend heavily
on intracellular calcium stores in the sarcoplasmic reticulum
(SR) to release calcium during ECC. To test the possibility
that Dmp1 null muscles are weaker due to alterations in SR
calcium handling, we treated each of these muscles with 5mM
caffeine, an agent that effectively releases calcium from the SR.
Interestingly, we found that both EDL and SOL muscles had
reduced responses to caffeine, suggesting defects in the ECC
that are responsible for the muscle weakness (Figures 1E, 2D;
P < 0.05).
Cardiac Muscle
Dmp1 null mice had a significantly reduced body mass (−40.1%)
and heart weight (−23.8%) when compared to WT mice
(Figures 3A,B; P< 0.05). However, the proportion of HW size to
BW size (the HW/BW ratio) was significantly increased (27.3%)
in the Dmp1 null mice compared to WT (Figure 3C; P < 0.05).
Since we observed an increase in relative heart size in Dmp1
null mice, and increases in HW/BW ratios can be indicative of
pathological hypertrophy, we analyzed ventricular heart tissue for
genetic markers of pathological hypertrophy and remodeling as
well as changes in contractility. We did not observe an increase
in genes associated with pathological cardiac hypertrophy (ANP,
Sk. Act., β-MHC) or genes associated with fibroblasts (vimentin)
or remodeling (collagen) (Figure 4; P > 0.05) in Dmp1 null
mice compared to WT mice. These data suggest that the
proportionately larger hearts from Dmp1 null did not show
classical markers of pathological hypertrophy.
Next, we tested ex-vivo whole heart contractility using
an isolated organ bath with stimuli that produced maximal
contractions. Maximal tension (adjusted for HW) at 1 Hz
stimulation was not statistically different betweenWT andDmp1
null mice hearts (Figure 5A; P > 0.05). However, there was
a decrease in the maximum slope of the contractile waveform
indicating that the maximum rate of force development was
reduced in the Dmp1 null mice hearts compared to WT
(Figure 5B; P > 0.05). There was no difference in the rate of
relaxation (Tau) between hearts (Figure 5C; P> 0.05). These data
show that the Dmp1 null hearts were able to contract to the same
extent per g of heart weight, but the rate of force development was
reduced. Overall, the contractile data support the gene expression
data indicating that there was no overt cardiac pathology at the
time-point studied since there was little dysfunction in maximal
contraction.
Vascular Smooth Muscle
Isometric tension myography was conducted on isolated aortic
rings to determine if there were differences in contraction or
relaxation of the vasculature in the Dmp1 null mice compared
to WT. No statistical differences were observed in contraction
responses to increasing concentrations of either PGF2α or
serotonin comparing WT and Dmp1 null (Figures 6A,B; P >
0.05). When vessels were precontracted with PGF2α, there was no
difference in relaxation produced by increasing concentrations
of ACh indicating that there was no impairment of aortic
endothelium in Dmp1 null mice (Figure 6C; P > 0.05).
Likewise, the nitric oxide donor (endothelium-independent
relaxation) induced a similar relaxation response between WT
and Dmp1 null (Figure 6D; P > 0.05). Collectively, these results
demonstrate there was no impairment in vascular smoothmuscle
or endothelium of aorta in Dmp1 null mouse compared to
the WT.
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FIGURE 1 | Dmp1 null mice are smaller and the EDL muscles of Dmp1 null are weaker than WT. (A) Average body weights of WT and Dmp1 null. (B)
Average values of the dry blotted wet weights of EDL muscles from WT and Dmp1 null mice illustrate the decreased mass in EDL from the null mice. (C) However,
there was no difference in EDL weights once normalized to body weight (BW). (D) The physiological cross sectional area normalized force of EDL muscles from the
Dmp1 null is significantly lower than that produced by the EDL muscles from the WT mice suggesting that there may be additional factors beyond atrophy that
contribute to muscle weakness. (E) Average caffeine-induced contractions in EDL muscles from Dmp1 null show that muscles from the null mice produce significantly
lower levels of force in response to SR calcium release induced by caffeine. These data reinforce the hypothesis that factors such as problems in ECC may account
for the loss of force in the EDL. Data are mean ± SE; n = 7 (4 male/3 female); *indicates statistical significance compared to WT (P < 0.05).
DISCUSSION
ARHR patients are known to display rickets/osteomalacia, but
little is known about skeletal muscle or cardiovascular function
in ARHR or other heritable diseases of hypophosphatemia.
In this study, for the first time, the function of skeletal and
cardiac muscle as well as vascular smooth muscle function in
the Dmp1 null mouse model of ARHR was analyzed. Similar to
ARHR patients, these mice display deformed bones and growth
plates, shorter and wider long bones, bony protrusions, delayed
blood vessel invasion of bone, altered canaliculi, impaired fluid
flow through the canaliculi, less organized osteocytes, and a
decreased mineral to matix ratio (Ling et al., 2005; Rios et al.,
2005; Feng et al., 2006). Understanding the muscle function in
this condition has great significance for patients suffering from
rickets/osteomalacia.
Skeletal Muscle Phenotype
We found that skeletal muscle force in both a fast-twitch and
a slow-twitch muscle were reduced. The Dmp1 null mice and
muscles were smaller than WT, but even after correcting for
the cross-sectional area of the muscle, we found that the Dmp1
null EDL and SOL muscles were significantly weaker indicating
that atrophy alone cannot account for the reduction in force
production. Since this phenomenon was observed in both the
EDL and SOL, the mechanism of impairment likely involved
general mechanisms of skeletal muscle contraction and was not
due to specific fiber type differences. Both muscle types had
reduced tetanic force in response to caffeine administration
compared to WT demonstrating that the calcium release
mechanism during ECC was impaired. Some possibilities for
this impaired ECC could be reductions in calcium levels in the
SR, problems in dihydropyridine receptor (DHPR) interaction
with the ryanodine receptor (RyR), or alterations in proteins
(and/or their phosphorylation states) such as SERCA, the calcium
binding protein calsequestrin, RyR1, or myosin heavy chain.
These all are important future targets to analyze for both human
as well as animal studies involving genetic hypophosphatemic
diseases such as ARHR.
Patients suffering from osteomalacia/rickets have reported
muscle deficits (Schott and Wills, 1976; Veilleux et al., 2012). To
our knowledge, there have been no detailed studies specifically
documenting muscle function in ARHR patients, but it has
been found that hypophosphatemic rickets patients have reduced
function in lower limb muscle function tests (Veilleux et al.,
2012). Similarly, calf muscle force, but not cross-sectional
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FIGURE 2 | SOL muscles from Dmp1 null are smaller and weaker than
WT. (A) Average values of the dry blotted wet weights of SOL muscles from
WT and Dmp1 null mice illustrate decreased mass in SOL from the null mice.
(B) The SOL muscles were still smaller than WT even after normalizing for
body weight (BW). (C) The physiological cross sectional area normalized force
of SOL muscles from the Dmp1 null mice is reduced by 2/3 when compared
to SOL muscles from WT mice suggesting that there may be additional factors
beyond atrophy that contribute to muscle weakness. (D) Average caffeine
induced contractions in SOL muscles from Dmp1 null show that muscles from
the null mice produce significantly lower levels of force in response to SR
calcium release induced by caffeine. These data reinforce the hypothesis that
factors such as problems in ECC may account for some of the loss of force in
the SOL. Data are mean ± SE; n = 7 (4 male/3 female); *indicates statistical
significance compared to WT (P < 0.05).
area, was lower in X-linked hypophosphatemia (XLH) patients
compared to controls, while the distal tibia had an increased
bone cross sectional area, but lower cortical bone mineral density
(Veilleux et al., 2013). In addition, there have been skeletal
muscle studies in rodent models of XLH (using the Hyp mouse).
XLH results from mutations in PHEX which then allows FGF23
to go unregulated and reduces phosphate levels comparable to
ARHR. The Hyp mouse model of XLH rickets has reduced grip
strength as well as reduced spontaneous movement (Aono et al.,
2011). Our data in the ARHR model would thus seem to have
consistency to the findings in XLH and suggest a shared cause.
The underlying direct mechanism causing the changes in
muscle function we observed still needs to be elucidated. It
is possible that the changes in plasma ion concentrations in
the Dmp1 null are the direct cause for the muscle phenotype.
Previous reports from our laboratory and others have measured
serum concentrations of various ions and hormones in the blood
at the same approximate age as themice in this study. The average
values from these studies are as follows: FGF23 = 1169 ± 158
pg/ml; Pi = 4.4 ± 0.6 mg/dl; Ca2+ = 7.9 ± 0.4 mg/dl; 1,25
Vit. D = 65.2 ± 27 (Feng et al., 2006; Liu et al., 2008; Lu
et al., 2011). Changes in phosphate, calcium, or Vitamin D
could play a role in altering the function of the skeletal muscle,
although reduced phosphate alone was the primary mechanism
for causing weakness in slow-twitch muscle fibers in rats with
severe vitamin D deficiency (and hypocalcemia) (Schubert and
Deluca, 2010). The potential mechanisms for hypophosphatemic
muscle weakness are still largely unresolved, but likely involve
the metabolism of ATP, phosphorylation of myosin and actin
filaments, alteration in ion pumps and calcium handling, or
changes in mitochondrial function (Fuller et al., 1976; Brautbar
et al., 1983; Hettleman et al., 1983; Johnson et al., 1989). However,
an important point to note is that the muscles in our experiments
were placed in a Ringer’s solution with normal phosphate and
calcium for each muscle bath experiment and had time to
equilibrate after removal from the animal. Furthermore, Veilleux
et al. found no significant influence of serum phosphorus, PTH,
or treatment status on the muscle weakness identified in their
hypophosphatemic patients (Veilleux et al., 2012). Nevertheless,
it is possible that the chronic exposure to low phosphate may
have remodeled the muscles to work with lower force or at lower
phosphate levels.
Changes in bone structure as well as inactivity may also
induce the skeletal muscle phenotype in the Dmp1 null. In
hypophosphatemic patients with muscle function deficits, it was
observed that patients without lower limb deformities had better
muscle function than those with severe deformities (Veilleux
et al., 2012). In the case of the Dmp1 null, there is likely more
to the mechanism than simply muscle disuse, as atrophy alone
could not account for the muscle weakness in our studies;
however, it remains to be determined if muscles are, in part,
adapting to altered bone. This hypothesis may not be able to
explain the findings in our organ bath system as the muscles
were tested independently of bone attachment and at optimal
stretch.
It is also possible that the altered bone phenotype in the
Dmp1 null may have impacted normal bone-muscle crosstalk
through paracrine and endocrine agents (Isaacson and Brotto,
2014). Our research group has been interested in the crosstalk
between bone and muscle and the role of bone health in
directly contributing to skeletal muscle and cardiovascular
health. While it is well-accepted that muscle contraction can
increase mechanical forces on bone and lead to altered bone
density, it is becoming more commonly accepted that bone can
act in an endocrine manner to communicate with organs such
as the kidney, brain, and muscle to alter systemic physiological
functions (Brotto and Johnson, 2014). As far as bone-muscle
interactions, Gorski et al. (2015) have recently shown that
conditional deletion of Mbtps1 protease in bone results in
increased mass, contraction force, and increased regenerative
capacity in SOL muscles of 10–12, but not 3 month-old mice.
There were no changes in the MBTPS1 protease expression
observed in SOL muscles and it was concluded that altered
bone-muscle crosstalk was involved in producing the changes
in muscle phenotype. Specifically, bone can secrete factors
in a paracrine manner which has important implications for
local biochemical crosstalk between bone and skeletal muscle.
Using fluorescent tracers, the periosteum has been shown to
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FIGURE 3 | Dmp1 null mice have altered heart weight to body weight ratios. Dmp1 null mice showed reduced heart weights (A) and body weights (B). (C)
While both heart weight and body weights were reduced, heart weight to body weight ratio was higher in the Dmp1 null mice compared to WT mice. Data are mean ±
SE; n = 10 (7 male/3 female); *indicates statistical significance compared to WT (P < 0.05).
be permeable to molecules under 40 kDa such as PGE2, IGF-
1, IL-15, and FGF-2 (Lai et al., 2014). Our research group has
shown that PGE2 is an important factor in MLO-Y4 osteocyte-
like conditioned media which accounts for changes in myoblast
growth, differentiation, and proliferation (Mo et al., 2012, 2015).
Additionally, another group has shown that bone morphogenic
proteins are important regulators of skeletal muscle mass (Sartori
and Sandri, 2015). Beyond paracrine factors, bone cells such as
osteocytes and osteoblasts are also well-known to secrete various
hormones such as FGF23, osteocalcin, and sclerostin that can
target multiple organs such as the kidney, parathyroid, brain,
and adipose. FGF23 in particular has received special attention
recently due to its ability to directly influence the heart and
vasculature (Faul et al., 2011; Touchberry et al., 2013; Silswal
et al., 2014). Interestingly, treatment with anti-FGF23 antibody
therapy was able to improve muscle weakness and the reduced
activity in the Hyp mouse (Aono et al., 2011). However, it
remains to be determined if FGF23 has a direct action on skeletal
muscle.
Lastly, it is possible that deletion of Dmp1 directly altered
the muscle phenotype. This is likely less probable as DMP1 has
been shown to be expressed primarily in bone cells such as
osteocytes and osteoblasts. There is a report demonstrating that
DMP1 is also expressed in some soft tissues such as the brain,
pancreas, kidney, and liver, with highest expression in the brain
and pancreas (Terasawa et al., 2004) and a report demonstrating
DMP1 expression in coronary arteries (Van Venrooij et al.,
2014). Terasawa et al. (2004), showed low gene expression
in skeletal muscle tissue, however, it was not clear what cell
type may be responsible. To our knowledge there have been
no reports demonstrating expression in cardiac myocytes. We
hypothesize that the global deletion of Dmp1 is most likely
not responsible for the phenotype as other animal models of
reduced bone formation or hypophosphatemia such as Hyp
mice also display muscle weakness. In the future it will be
interesting to determine if the Hyp mouse and Dmp1 null
mouse have similar specific molecular mechanisms inducing the
phenotype.
FIGURE 4 | No increase in genes involved in hypertrophic signaling or
remodeling in the Dmp1 null mice. To dermine if the increase in heart
weight to body weight ratio in Dmp1 null mice was due to pathological cardiac
remodeling, we determined the expression of hypertrophy-associated genes
atrial natriuretic peptide (ANP), skeletal muscle α-actin (SkAct), β-myosin heavy
chain (βMHC), and α-myosin heavy chain. Dmp1 null mice did not show any
significant elevations in these markers of hypertrophy. Dmp1 null mice did not
exhibit any changes in the expression of sarcoplasmic endoplasmic reticulum
calcium ATPase (SERCA), which is known to be downregulated in heart failure.
Lastly, Dmp1 null mice did not show an increased expression of vimentin
(marker of cardiac fibroblasts) or collagen 1a1 (marker of fibrosis). Data are
mean ± SE; n = 5 (male); P > 0.05.
Cardiovascular Effects
While there have been clinical studies linking lower bone mass
with a greater risk of heart failure (Pfister et al., 2014), there
have been very few studies analyzing cardiovascular function
in ARHR or specifically studying cardiac muscle function in
bone disease. One study with young XLH subjects found left
ventricular hypertrophy in 7 of 13 patients (diagnosed by EKG or
ultrasonography) and also an increase in diastolic blood pressure
during an exercise stress test (Nehgme et al., 1997). Therefore,
there was strong rationale to determine if changes in cardiac or
vascular function occur in this ARHR model.
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FIGURE 5 | Comparison of cardiac muscle contractile waveforms between WT and Dmp1 null. (A) There were no differences in isometric force production
corrected for heart weight between WT and Dmp1 null mice. (B) Dmp1 null mice did present with a reduced slope, suggest a reduction in the rate at which isometric
tension is developed. (C) There were no differences in tau (rate of relaxation), between WT and Dmp1 null mice, suggesting calcium reuptake is unaltered in Dmp1 null
mice. Data are mean ± SE; n = 10 (7 male/3 female); *indicates statistical significance compared to WT (P < 0.05).
FIGURE 6 | Dmp1 null mice do not display impaired aortic contractions or relaxation. Contractile response curves to prostaglandin F2α (PGF2α) (A) and
5-hydroxytryptamine (5-HT) (B) were not different between WT and Dmp1 null mice suggesting that smooth muscle function was normal. Relaxation response curves
to acetylcholine (ACh) (C) and the NO donor, sodium nitroprusside (SNP) (D) on PGF2α-precontracted aortic rings from WT and Dmp1
−/−mice were also not different
suggesting there was not impairment in endothelial-dependent or endothelial-independent smooth muscle relaxation. Data are mean ± SE; n = 13 (8 male/5 female),
P > 0.05.
The hearts in the Dmp1 null mice displayed an increase
in HW/BW ratio indicative of hypertrophy. Gene expression
analysis of markers for pathological hypertrophy or remodeling
(fibrosis), however, were not elevated. There was also no
difference in the total contractile force produced after correcting
for the heart weight between WT and Dmp1 null. These results
would indicate that a pathological condition was not present at
the time point studied. Interestingly, Nehgme et al. (1997) as well
as Vered et al. (1990) found no changes in left ventricular ejection
fraction in XLH patients despite cardiac hypertrophy being
present. Further research remains to determine if our findings
point toward an adaptation of physiological hypertrophy, a
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difference in growth and development between body and heart
mass, or if a pathology would arise later in age of the mouse.
While the total force was not different, the rate of force
development was reduced. Similar to our findings in skeletal
muscle, this result may indicate some dysfunction in cardiac
muscle ECC or an adaptation of the muscle to the conditions.
These differences appear to only extend to excitation as the rate of
relaxation was not altered. We paced these hearts at 1 Hz in order
to reduce myocardial stress and oxygen demand on the heart,
similar to standard protocols (Kirchhefer et al., 2004; Gonzalez-
Munoz et al., 2008; Touchberry et al., 2010). Since there was a
reduction in rate of force development, it is possible that hearts
stressed at higher rates (reduced diastolic time) may show a more
dramatic phenotype or cardiac weakness over time. It is also
possible that cardiac muscle did not show as extreme a phenotype
as skeletal muscle because of differences in ECC such as a larger
reliance on extracellular vs. intracellular calcium in cardiac vs
skeletal muscle.
Our group and others have documented that FGF23 can
induce cardiac hypertrophy as well as alter calcium handling and
contractility (Faul et al., 2011; Touchberry et al., 2013; Grabner
et al., 2015). Work by Faul et al. has shown that exogenous
FGF23 at 15,000–100,000 pg/ml produced hypertrophy in vitro
as well as ex-vivo (Faul et al., 2011; Grabner et al., 2015). Since
the levels of FGF23 in the Dmp1 null mouse have been measured
between ∼900 and 1400 pg/ml at 5–6 months of age (Feng et al.,
2006; Liu et al., 2008; Lu et al., 2011), it is possible that these
hearts did not develop pathological hypertrophy because FGF23
did not reach high enough serum levels or that FGF23 at lower
serum levels works in concert with other factors (such as those
present in chronic kidney disease–CKD) to induce pathological
hypertrophy.
There were no significant differences in vascular function in
the Dmp1 null aorta. Nehgme et al. in their study with XLH
patients did observe increased diastolic blood pressure indicative
of vascular dysfunction (Nehgme et al., 1997). They hypothesized
that calcification of arterial walls may have altered vessel
compliance and production of vasodilators resulting in increases
in systemic vascular resistance and compensatory hypertrophy.
Since we did not observe any endothelial impairment or
dysfunction, it is possible that ARHR does not directly induce
vascular dysfunction and that vascular changes may have been
due to the treatments that XLH patients received. This is
supported by research showing vascular dysfunction such as
calcification tends to occur due to changes in high phosphate
(Scialla et al., 2013). Interestingly, we have shown that treatment
with 9000 pg/ml FGF23 can induce endothelial dysfunction in
mouse aorta and have observed similar dysfunction in a mouse
model of CKD (Silswal et al., 2014). Again, it is possible that the
levels of FGF23 in the Dmp1 null were not high enough to cause
dysfunction or that additional factors present during CKD also
play a role.
In summary, Dmp1 null mice show dramatic skeletal muscle
weakness, reductions in SOL size, increased HW/BW ratio, and
reduced cardiac muscle rate of force development but not total
force. Importantly, we have shown that in an ARHR mouse
model, there are muscle phenotypes in addition to the skeletal
phenotype. It will be critical that ARHR as well as other patients
with hypophosphatemia and bone disease are checked for muscle
function in addition to monitoring bone health.
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